SCINAI IMMUNOTHERAPEUTICS LTD. Income (Loss) from Continuing Operations, Net of Tax, Including Portion Attributable to Noncontrolling Interest
SCINAI IMMUNOTHERAPEUTICS LTD. (SCNI) reported Income (Loss) from Continuing Operations, Net of Tax, Including Portion Attributable to Noncontrolling Interest of $8.13 million for the 12-month period ending 2022-12-31, per its 10-K filed 2023-04-17.
Discontinued › Expense Statement › Operating Expenses
us-gaap:IncomeLossFromContinuingOperationsIncludingPortionAttributableToNoncontrollingInterest · last filed 2023-04-17
- SCINAI IMMUNOTHERAPEUTICS LTD. income (loss) from continuing operations, net of tax, including portion attributable to noncontrolling interest for fiscal 2022 was $8.13M, a 157.93% increase from fiscal 2021.
- SCINAI IMMUNOTHERAPEUTICS LTD. income (loss) from continuing operations, net of tax, including portion attributable to noncontrolling interest for fiscal 2021 was $3.15M.
| Period end | Income (Loss) from Continuing Operations, Net of Tax, Including Portion Attributable to Noncontrolling Interest 12 month |
|---|---|
| 2022-12-31 | $8.13M 10-K · filed 2023-04-17 |
| 2021-12-31 | $3.15M 10-K · filed 2023-04-17 |